BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27292433)

  • 1. Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells.
    Zhou W; Feng X; Han Han ; Guo S; Wang G
    Sci Rep; 2016 Jun; 6():28004. PubMed ID: 27292433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
    Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
    Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.
    Fröhlich LF; Mrakovcic M; Smole C; Lahiri P; Zatloukal K
    PLoS One; 2014; 9(3):e91558. PubMed ID: 24618889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
    Yerbes R; López-Rivas A
    Invest New Drugs; 2012 Apr; 30(2):541-7. PubMed ID: 21107885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
    Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
    Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
    PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAHA/TRAIL combination induces detachment and anoikis of MDA-MB231 and MCF-7 breast cancer cells.
    Lauricella M; Ciraolo A; Carlisi D; Vento R; Tesoriere G
    Biochimie; 2012 Feb; 94(2):287-99. PubMed ID: 21835222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
    Feng X; Han H; Zou D; Zhou J; Zhou W
    Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
    Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
    Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors.
    Cao H; Cheng Y; You L; Qian J; Qian W
    Mol Med Rep; 2013 Jun; 7(6):1838-44. PubMed ID: 23620163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines - An Isobolographic Analysis.
    Wawruszak A; Luszczki JJ; Grabarska A; Gumbarewicz E; Dmoszynska-Graniczka M; Polberg K; Stepulak A
    PLoS One; 2015; 10(11):e0143013. PubMed ID: 26580554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SAHA-induced TRAIL-sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture.
    Arhoma A; Chantry AD; Haywood-Small SL; Cross NA
    Exp Cell Res; 2017 Nov; 360(2):226-235. PubMed ID: 28890292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Knockdown of TRAIL-DR5 gene inhibits autophagy of ER-positive MCF-7 breast cancer cells induced by SAHA].
    Han H; Zhou H; Sun W; Liu C; Hou X; Zhou W
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Nov; 33(11):1504-1510. PubMed ID: 29268854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis.
    Murahari S; Jalkanen AL; Kulp SK; Chen CS; Modiano JF; London CA; Kisseberth WC
    BMC Cancer; 2017 Jan; 17(1):67. PubMed ID: 28109246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment.
    Meng X; Brachova P; Yang S; Xiong Z; Zhang Y; Thiel KW; Leslie KK
    PLoS One; 2011; 6(6):e20920. PubMed ID: 21687633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
    Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
    Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.